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Patients’ preferences for the management of non-metastatic prostate
cancer: discrete choice experiment
Mark Sculpher, Stirling Bryan, Pat Fry, Patricia de Winter, Heather Payne, Mark Emberton
Abstract
Objective To establish which attributes of conservative
treatments for prostate cancer are most important to men.
Design Discrete choice experiment.
Setting Two London hospitals.
Participants 129 men with non-metastatic prostate cancer,
mean age 70 years; 69 of 118 (58%) with T stage 1 or 2 cancer
at diagnosis.
Main outcome measures Men’s preferences for, and trade-offs
between, the attributes of diarrhoea, hot flushes, ability to
maintain an erection, breast swelling or tenderness, physical
energy, sex drive, life expectancy, and out of pocket expenses.
Results The men’s responses to changes in attributes were all
statistically significant. When asked to assume a starting life
expectancy of five years, the men were willing to make
trade-offs between life expectancy and side effects. On average,
they were most willing to give up life expectancy to avoid
limitations in physical energy (mean three months) and least
willing to trade life expectancy to avoid hot flushes (mean 0.6
months to move from a moderate to mild level or from mild to
none).
Conclusions Men with prostate cancer are willing to participate
in a relatively complex exercise that weighs up the advantages
and disadvantages of various conservative treatments for their
condition. They were willing to trade off some life expectancy to
be relieved of the burden of troublesome side effects such as
limitations in physical energy.
Introduction
Several situations exist where patients face trade-offs between
the risks and benefits of alternative therapies.1 The conservative
management of men with organ confined or locally advanced
prostate cancer is such a situation. Men diagnosed at a stage
when radical treatments such as prostatectomy or radiotherapy
are inappropriate face several treatment options, including
watchful waiting or oral steroidal or non-steroidal antiandrogen
monotherapy.2 Many patients choose castration, performed
medically rather than surgically. Alternatively, there is the option
of antiandrogen treatment combined with medical or surgical
castration.
To make an informed choice, men need to be able to weigh
up the slight differences in effectiveness of treatment against a
spectrum of side effects associated with alternative strategies. For
example, non-steroidal antiandrogen monotherapy offers
potential advantages over castration for impotence, loss of libido,
and hot flushes, but these may be achieved at the cost of an
increased risk of gynaecomastia and breast pain.3
Individuals’ preferences for alternative treatments need to be
considered in the light of the attributes of the treatments.
Discrete choice experimentation, an approach for elicitation of
preferences, is now being used widely in health care.4 5 This
approach identifies the key characteristics of alternative
treatments, such as hot flushes, and selects a series of levels for
each (for example, absent, mild, moderate). Respondents choose
from several options, each of which details a series of attributes at
different levels. The relative importance of attributes to individu-
als and the trade-offs made between them, can be assessed by
changing the levels of the attributes and asking participants to
make their choice again. Findings on the reliability and validity of
discrete choice experimentation in healthcare settings are
encouraging.6 7 We used discrete choice experimentation to elicit
treatment related preferences in a sample of men with
non-metastatic prostate cancer.
Methods
Pilot study
Before the main study, we conducted a two phase pilot study in
men with prostate cancer. Fourteen men were recruited into the
first phase and were interviewed by a trained research nurse. On
the basis of these interviews eight attributes were selected for the
main study: diarrhoea, hot flushes, ability to maintain an
erection, breast swelling or tenderness, physical energy, sex drive,
life expectancy, and out of pocket expenses. In the second phase,
nine men were asked to complete a questionnaire based discrete
choice experiment with these attributes; there was also a brief
unstructured interview with a research nurse. Several men did
not understand the nature of the exercise and were only able to
complete exercise with guidance from the research nurse. We
therefore decided to use an interview format for the main study.
Study format
The attributes and levels used in the exercise are described on
bmj.com. We chose mild and moderate levels only: it was
explained to patients that therapy would be changed in a severe
event. The mild level included symptoms that would not interfere
with work, study, housework, family, or leisure activities and the
moderate level included symptoms that would.
A trained research fellow conducted the interviews, during
which personal data on the patients were collected (data were
also taken from medical records). The men were presented with
two treatment options, each containing a set of attributes at spe-
cific levels. The interviewer read out the pair wise options and
Treatment attributes and levels and probit models are on bmj.com
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used show cards as prompts to help the men choose the options
they preferred (table 1).
We divided the exercise into two parts to avoid overburden-
ing patients with too many attributes for an option. The first part
included three unique attributes—the ability to maintain an erec-
tion, physical energy, and libido. The second part included three
unique attributes—diarrhoea, hot flushes, and breast tenderness.
Both parts included two common attributes—life expectancy and
a one off out of pocket expense.
The men had to assume a life expectancy of five years,
estimated as the average for the sample considering the mean
age (70 years) and clinical stage of disease. The clinical stage was
typically not detected by screening but rather diagnosed on the
basis of problems relating to progression of the cancer. The five
year average was justified because the sample included men with
T1 or T2 disease with an estimated seven year survival probabil-
ity of 65% and men with T3 or T4 disease with a five year survival
probability of 30%.8 9 The two parts of the exercise each
contained eight pair wise options. We prepared eight different
versions of the questionnaire, each representing a new
experimental design (orthogonal main effects). Each version of
the questionnaire presented different levels of the cost attribute
to allow a larger number of intervals between cost levels across
the survey. Study patients were randomly allocated to one of the
questionnaires.
Study sample
Our study sample was patients with non-metastatic prostate can-
cer who had or had never received antiandrogen therapy; there
were no exclusion criteria. Potential participants were identified
from records at the Middlesex Hospital, London. They were con-
tacted in writing to obtain written informed consent.
Respondents were asked to make an appointment for an
interview at the Middlesex Hospital.
Analysis
We analysed the discrete choice exercise by taking each choice
between pair wise options as a specific observation. Hence each
respondent provided a maximum of 16 observations. Given the
non-independence of the data provided by the same respondent,
a random effects probit model was used. Two separate models
were specified (one for each group of attributes), with the choice
responses as the binary dependent variable and the difference in
levels for each of the attributes as the independent variables (see
bmj.com). The specification of the experiment precluded the
testing for interactions between attributes, but we explored the
interactions between attributes and patient characteristics (age,
prostate specific antigen level, and T stage of cancer at diagnosis).
Results
Between 24 May and 8 September 2000, we invited 180 men to
participate in our study. Of these, 129 were interviewed.
Participants were similar to those who declined for mean age
and T stage at diagnosis. Table 2 shows the characteristics of the
participants.
Discrete choice experiment
Table 3 shows the results of the first part of the exercise. The
coefficients for the unique attributes were all statistically
significantly different from 0; negative values for libido,
maintaining an erection, and physical energy indicate that the
more severe the problems, the less likely the patient is to prefer
that scenario; negative values for out of pocket expenses indicate
that the higher the costs, the less likely the patient is to prefer that
scenario. Positive values for life expectancy indicate that the
greater the life expectancy the more likely the patient is to prefer
that scenario. The only statistically significant interaction was
between ability to maintain an erection and age; the positive
value indicates that older men were less likely to be influenced by
the ability to maintain an erection in choosing their preferred
scenario.
Table 4 shows the results of the second part of the exercise,
which also considered the unique attributes of diarrhoea, hot
flushes, and breast tenderness. The coefficients for the attributes
Table 1 Example of show card used in discrete choice experiment
Option A Option B
Part 1
Sex drive or libido Diminished Diminished
Ability to get or maintain
erection
No problems No problems
Physical energy Lacking “pep” No problems
Treatment cost to you
personally
£400 £275
Life expectancy Option A better by two months
Part 2
Diarrhoea Present, moderate Absent
Hot flushes Present but mild Present but mild
Breast swelling or tenderness Present Present
Treatment cost to you
personally
None £150
Life expectancy Option A better by two months
Table 2 Characteristics of men (n=129). Values are numbers (percentages)
unless stated otherwise
Characteristic Descriptive statistic
Mean (SD) age (years) 70 (6.8)
T stage at diagnosis:
T1 25/118 (21)
T2 44/118 (37)
T3 35/118 (30)
T4 3/118 (2)
Median (interquartile range) prostatic specific
antigen level
1.3 (0.5-5.9)
In stable relationship 93/126 (74)
Work status:
Employed 34/127 (27)
Retired 90/129 (70)
Other 4/129 (3)
Continuing education after minimum age 78/127 (61)
Degree or equivalent qualification 55/127 (43)
Table 3 Results of first part of discrete choice exercise
Variable Coefficient (95% CI) SE P value
Libido −0.3089
(−0.5719 to −0.0460)
0.1342 0.021
Ability to maintain erection −0.4243
(−0.5321 to −0.3165)
0.0550 <0.001
Physical energy −0.7032
(−0.8219 to −0.5845)
0.0606 <0.001
Out of pocket expenses −0.0007
(−0.0014 to −0.0001)
0.0003 0.017
Life expectancy 0.2336 (0.1707 to 0.2966) 0.0321 <0.001
Interaction between ability to
maintain erection and age
0.2184 (0.0934 to 0.3433) 0.0637 0.001
Constant −0.0541
(−0.1459 to 0.0376)
0.0468 0.248
No of observations 1000; 194.92; P<0.0001*
*2 test.
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were all statistically significantly different from zero. Negative
values for diarrhoea, hot flushes, and breast tenderness indicate
that the more severe the problem the less likely the patient is to
prefer that scenario. None of the interaction terms were statisti-
cally significantly different from zero.
Table 5 shows the marginal rates of substitution between life
expectancy and other attributes—that is, how much life
expectancy the men were willing to trade off to achieve an
improvement by one level in one of the other attributes. For
example, men were willing to trade off 1.8 months of life expect-
ancy to change diarrhoea from a moderate to mild level or from
mild to absent. Because the levels of severity differed between
attributes, marginal rates of substitution between attributes
should be compared with caution. The least important marginal
rates of substitution were for hot flushes and the most important
were for physical energy.
Discussion
Men with prostate cancer are willing to participate in the
relatively complex exercise of discrete choice experimentation to
weigh up the benefits and risks of various conservative
treatments, irrespective of the stage of cancer or whether they
had received such treatment. To our knowledge, our study is the
first to elicit preferences from patients with prostate cancer using
discrete choice experimentation, and provides further evidence
that this approach can be applied successfully in health care. A
novel feature of our study was the use of two groups of attributes.
This allowed the choices to be kept relatively simple (maximum
of six attributes), and the inclusion of a common core of two
attributes (cost and life expectancy) ensured trade-offs across all
attributes.
The men were willing to trade off some life expectancy to be
relieved of side effects. Men with metastatic cancer were not
included in the study, so no patients faced imminent death, with
life expectancy ranging from around 2 to 10 years. Given the dif-
ficulty in estimating, and potential ethical problems in
presenting, life expectancy for each patient, the men were asked
to assume a life expectancy of five years (the average in the
group) as a starting point. The size of the trade-offs between life
expectancy and the other attributes should be treated with
caution because men with a longer or shorter life expectancy
than five years may have indicated different preferences if their
actual life expectancy had been presented to them.
The results are averaged across the sample and so there is
inevitable variation between the men. Our results are therefore
no substitute for careful assessment of individual patient prefer-
ences in a clinical setting but do provide some basis for clinicians
to prioritise issues they discuss with patients. The implications on
physical energy from conservative treatment, for example, may
be an important starting point for decisions on treatment.
Our findings could be used by clinicians to help patients
choose between conservative treatments; knowing about the
preferences of other men with prostate cancer might help
patients to clarify their own thoughts. Our findings could also
help in the design of new studies in prostate cancer.
We looked at the application of discrete choice experiments
in prostate cancer only. The ability and willingness of men to
engage in this exercise is encouraging for future research.
Perhaps the most common therapeutic dilemma that patients
and clinicians face is the timing of androgen suppression. Should
a patient start therapy early, once progression of prostate cancer
has been identified? The potential benefits of this approach
might include a slowing down of disease progression and
perhaps reducing the likelihood of death related to the cancer.
Alternatively, the patient could defer treatment for an agreed
time. This would avoid the immediate side effects of treatment
and possibly reduce the medium to long term adverse effects.
This type of trade-off is made by many patients with progression
of disease everyday, and discrete choice experimentation could
gain some insight into the way patients make this difficult choice.
We thank Rob Sheldon (Accent Marketing and Research) for help with the
design and analysis of the study, Wendy Coucill for her work on the pilot
study, and the patients.
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Table 4 Results of second part of discrete choice exercise
Variable Coefficient (95% CI) SE P value
Diarrhoea −0.4193
(−0.5454 to −0.2931)
0.0644 <0.001
Hot flushes −0.1225
(−0.2162 to −0.0287)
0.0479 0.010
Breast tenderness −0.4329
(−0.6147 to −0.2512)
0.0927 <0.001
Out of pocket expenses −0.0016
(−0.0025 to −0.0007)
0.0004 0.001
Life expectancy 0.2329
(0.1827 to 0.2832)
0.0256 <0.001
Constant 0.1278
(0.0262 to 0.2294)
0.0518 0.014
No of observations 992; 164.35; P<0.0001*
*2 test.
Table 5 Patients’ marginal rates of substitution between life expectancy and
other attributes
Attribute
Life expectancy willing to
forgo (months) Single level improvement
Diarrhoea 1.8 From moderate to mild or
from mild to absent
Hot flushes 0.5 From moderate to mild or
from mild to absent
Breast swelling 1.9 From present to absent
Loss of libido 1.3 From present to absent
Problems in maintaining an
erection:
Aged <70 years 1.8 From moderate to mild or
from mild to absent
Aged >70 years 0.9 From moderate to mild or
from mild to absent
Lack of energy or “pep” 3.0 From present to absent
What is already known on this topic
Various factors need to be considered in making
treatment decisions in prostate cancer
Patients’ views on which factors of treatment are
important to them and how they trade-off these
factors is under-researched
What this study adds
Men are willing to contemplate trading off life
expectancy to be relieved of the burden of side
effects such as limitations in physical energy
The preferences of older men are not the same as
those of younger men
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